NCT03122353 - BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis | Biotech Hunter

Enrollment

699

Participants

Timeline

Start Date

April 11, 2017

Primary Completion Date

November 15, 2017

Study Completion Date

November 15, 2017

Conditions

Scalp Psoriasis

Interventions

DRUG

Calcipotriene and betamethasone suspension

Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

DRUG

Taclonex

Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

DRUG

Placebo

vehicle used as placebo

Trial Locations (34)

15241

Site 24, Upper Saint Clair

18201

Site 28, Hazleton

23507

Site 22, Norfolk

27262

Site 09, High Point

29464

Site 35, Mt. Pleasant

29621

Site 07, Anderson

32792

Site 23, Winter Park

33012

Site 11, Hialeah

33027

Site 05, Miramar

33126

Site 26, Miami

33134

Site 25, Coral Gables

33175

Site 04, Miami

33486

Site 20, Boca Raton

33511

Site 01, Brandon

33609

Site 02, Tampa

33618

Site 03, Tampa

46168

Site 16, Plainfield

64506

Site 27, Saint Joseph

66061

Site 19, Olathe

70601

Site 33, Lake Charles

71913

Site 17, Hot Springs

75094

Site 08, Murphy

75234

Site 06, Dallas

78229

Site 15, San Antonio

Site 31, San Antonio

78759

Site 21, Austin

79902

Site 30, El Paso

80220

Site 34, Denver

84117

Site 10, Salt Lake City

89106

Site 14, Las Vegas

90036

Site 12, Los Angeles

91403

Site 18, Sherman Oaks

94538

Site 29, Fremont

02919

Site 32, Johnston

All Listed Sponsors

lead

Tolmar Inc.

INDUSTRY